| 31.75 |  -0.23 / -0.72% |
Data as of 4:00pm ET | Day’s Change |
| 31.75 |  0.00 / 0.00% |
Volume: 46.2K |
| QIAGEN Downgraded to Strong Sell - Analyst Blog May 21 / Zacks.com | SGEN's Adcetris under FDA Review - Analyst Blog May 16 / Zacks.com |
| Yet Another Acquisition for Bayer - Analyst Blog May 21 / Zacks.com | Cempra/Toyama Ink Deal - Analyst Blog May 15 / Zacks.com |
| ALKS July Options Begin Trading May 20 / TheStreet.com | Much Awaited Test Launch by Genomic - Analyst Blog May 15 / Zacks.com |
| Alkermes Stock Hits New 52-Week High (ALKS) May 20 / TheStreet.com | Myriad Soars Higher on Celeb Clout - Analyst Blog May 15 / Zacks.com |
| Biogen's Hemophilia BLA Accepted - Analyst Blog May 20 / Zacks.com | Isis Gets $3.5M Milestone Payment - Analyst Blog May 14 / Zacks.com |
| Previous close | 31.98 |
| Today’s open | 31.95 |
| Day’s range | 31.41 - 32.95 |
| Volume | 1,550,166 |
| Average volume (3 months) | 1,325,121 |
| Market cap | $4.3B |
| Dividend yield | -- |
| Earnings growth (last year) | -106.25% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +65.79% |
| Revenue growth (last year) | +108.95% |
| P/E ratio | NM |
| Price/Sales | 5.46 |
| Price/Book | 4.88 |
| Today’s change | Today’s % change | |
|---|---|---|
| SGENSeattle Genetics Inc | -0.58 | -1.62% |
| IDXXIDEXX Laboratories I... | -2.19 | -2.56% |
| ENDPEndo Health Solution... | -0.42 | -1.23% |
| THRXTheravance Inc | -1.31 | -3.49% |
| Next reporting date | May 23, 2013 |
| EPS forecast (this quarter) | -$0.06 |
| Annual revenue (last year) | $390.0M |
| Annual profit (last year) | -$113.7M |
| Net profit margin | -29.15% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Richard F. Pops |
President Shane Cooke |
Corporate headquarters Dublin, Dublin |
.
